Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
neoNRCC in Locally Advanced Rectal Cancer
NCT07521605Phase 2Not yet recruiting
- Sponsor
- Guangdong Provincial People's Hospital
- Start
- May 2026
- Primary completion
- Dec 2031
- Modality
- Immune Checkpoint Inhibitors, DNA Intercalators/Alkylators, Lipid-based Nanoparticles
- Countries
- 1
01
Overview
A Phase 2 trial of nanoliposomal irinotecan, capecitabine, camrelizumab in rectal cancer, sponsored by Guangdong Provincial People's Hospital. Planned start May 2026; status: not yet recruiting.
02
Drugs
nanoliposomal irinotecancapecitabinecamrelizumab
03
Conditions
rectal cancer
Beyond the preview
Go deeper on NCT07521605.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07521605.